Granted Patent
B2
US 8,754,092 · App. 13/487,594 · Granted Jun 17, 2014
Inhibitors of the hedgehog pathway
Inventors:
Suleyman Bahceci (San Mateo, CA); William Bajjalieh (San Francisco, CA); Jeff Chen (San Francisco, CA); Sergey Epshteyn (Fremont, CA); Timothy Patrick Forsyth (Hayward, CA); Tai Phat Huynh (New York, NY); Byung Gyu Kim (San Mateo, CA); James W. Leahy (San Leandro, CA); Matthew Sangyup Lee (San Francisco, CA); Gary L. Lewis (San Francisco, CA); Morrison B. Mac (San Francisco, CA); Grace Mann (San Mateo, CA); Charles K. Marlowe (Emerald Hills, CA); Brian Hugh Ridgway (Belmont, CA); Joan C. Sangalang (Mountain View, CA); Xian Shi (San Bruno, CA); Craig Stacy Takeuchi (Burlingame, CA); Yong Wang (Foster City, CA)
Assignee:
Exelixis Patent Company LLC
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention is directed to a compound of Formula I or a single isomer thereof; where the compound is optionally as a pharmaceutically acceptable salt, hydrate, solvate or combination thereof, in addition to methods of preparing a Compound of Formula I, and methods of using a Compound of Formula I to treat cancer.
Claims (2)
1. A method of treating leukemia, comprising administering to a patient in need thereof a therapeutically effective amount of N-{2-methyl-5-[(methylamino)methyl]phenyl}-4-[(4-phenylquinazolin-2-yl)amino]benzamide, having the structure
optionally as a pharmaceutically acceptable salt thereof, and optionally with a pharmaceutically acceptable carrier, excipient, or diluent.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 27, 2022
From: EXELIXIS PATENT COMPANY LLC
To: EXELIXIS, INC.
Reel/Frame 059752/0813 →
Continuity (4)
Provisional Application
60918160
· Mar 14, 2007
Provisional Application
60962617
· Jul 30, 2007